Published in final edited form as:

Angew Chem Int Ed Engl. 2005 September 12; 44(36): 5863–5866.

Efficient One-Step Synthesis of Biologically Related Lariat RNAs by a Deoxyribozyme**

Yangming Wang and Scott K. Silverman*

* Department of Chemistry, University of Illinois at Urbana-Champaign, 600 South Mathews Avenue, Urbana, IL 61801 (USA), Phone: (+1) 217-244-4489, Fax: (+1) 217-244-8024, E-mail: scott@scs.uiuc.edu

Keywords

deoxyribozymes; DNA; enzyme catalysis; lariat RNA; macrocyclization

Lariat RNAs are intermediates in RNA splicing as catalyzed by group II introns and the spliceosome.^[1,2] Lariats have a closed RNA loop incorporating a single 2'–5' linkage and a single-stranded oligonucleotide attached at the 3'-oxygen of the branch-site nucleotide (Figure 1a). Topologically, lariats are a subclass of 2',5'-branched RNAs, which do not necessarily have the closed loop that is characteristic of lariats. Due to their special topology, lariat RNAs are difficult to synthesize by any conventional chemical approach such as solid-phase synthesis,^[3] and even the simpler 2',5'-branched RNA core (without the closed loop of a lariat) is a significant challenge.^[4] Recently we reported artificial deoxyribozymes (DNA enzymes)^[5] that create branched RNAs in >90% yield by catalyzing the intermolecular reaction of an internal 2'-hydroxyl group with a 5'-triphosphate.^[6,7] Some of these deoxyribozymes are capable of synthesizing branched RNAs of wide sequence composition.^[8,9] When branch formation is intramolecular (i.e., macrocyclization using a single, linear RNA substrate), the product is a lariat (Figure 1b). Aside from using the biological splicing machinery itself, which is frequently impractical, no method exists for synthesizing biologically relevant lariat RNAs, which are often several hundred nucleotides in length and have extensive secondary structure^[10] that may interfere with loop formation. Indeed, most of our reported branch-forming deoxyribozymes—such as 7S11, which is widely useful for branched RNA synthesis^[8]—are not useful when provided with biologically derived RNA sequences as substrates (typically <1% yield of lariat; data not shown). In contrast to these difficulties, we report here that the 6BX22 deoxyribozyme can create two common classes of biological lariat RNAs efficiently in one step from readily available RNA substrates.

In previous efforts, we used in vitro selection^[11] to identify many deoxyribozymes that synthesize branched RNA.^[6–9,12] However, our selection procedure does not demand the particular ability to create lariats. One-step lariat formation is presumably more difficult than simple branch formation because the incipient RNA loop may clash sterically with the DNA structure, thereby inhibiting catalysis. We surveyed many of the branch-forming deoxyribozymes to determine their lariat formation capabilities. One of these deoxyribozymes, 6BX22,^[12] showed promise in this regard and was examined more carefully. The 6BX22

** This research was supported by the Burroughs Wellcome Fund (New Investigator Award in the Basic Pharmacological Sciences), the March of Dimes Birth Defects Foundation (Research Grant No. 5-FY02-271), the National Institutes of Health (GM-65966), the American Chemical Society Petroleum Research Fund (38803-G4), and the UIUC Department of Chemistry (all to S.K.S.). S.K.S. is a Fellow of The David and Lucile Packard Foundation. We thank Jonathan Staley (Univ. of Chicago) for the plasmid encoding the ACT1 intron RNA and Scott Stevens (Univ. of Texas at Austin) for the sample of debranching enzyme.

Supporting Information for this article is available on the WWW under <http://www.angewandte.org> or from the author.

deoxyribozyme has a specific 39-nucleotide DNA enzyme region embedded between Watson-Crick binding arms, as shown schematically in Figure 1b. 6BX22 was found to require Mn^{2+} ; no detectable RNA ligation activity was observed with any of Mg^{2+} , Ca^{2+} , Zn^{2+} , Fe^{2+} , Co^{2+} , Ni^{2+} , Cd^{2+} , or $[\text{Co}(\text{NH}_3)_6]^{3+}$ (all as chloride salts at 10 μM –10 mM; data not shown). The k_{obs} for 6BX22-catalyzed branch formation is $\sim 0.07 \text{ min}^{-1}$ ($t_{1/2} \sim 10 \text{ min}$) under the 20 mM Mn^{2+} , pH 7.5, 37 °C standard incubation conditions (see below). When compared with the background rate for the analogous DNA-templated reaction (i.e., a reaction using a DNA template that lacks an enzyme region between the DNA binding arms, for which $k_{\text{templated}} \approx 4 \times 10^{-7} \text{ min}^{-1}$), the rate enhancement $k_{\text{obs}}/k_{\text{templated}}$ is calculated as 2×10^5 .^[13] Thus 6BX22 clearly “catalyzes” branch formation versus merely templating of the reaction via increasing the effective molarity of the substrates, for which $k_{\text{obs}}/k_{\text{templated}}$ would be 1.^[5a]

Before studying 6BX22-catalyzed lariat RNA synthesis in detail, we examined the substrate sequence generality of this deoxyribozyme for branch formation. This reaction is simpler than lariat formation because loop closure is not required. The selection procedure in which 6BX22 was identified^[12] used RNA substrates that correspond to the conserved branch-site sequences of yeast spliceosomal substrates (Figure 2a), which are common models for understanding RNA splicing.^[2] Systematic experiments revealed that sequence changes outside of the conserved RNA elements are tolerated well by 6BX22, indicating that this DNA enzyme is general for branch formation with yeast spliceosomal substrates (Figure 2b). Most nucleotide changes within the conserved regions are also tolerated. For example, the branch-site nucleotide itself may be changed from A to C or U with nearly equivalent ligation efficiencies (Figure 2c). A branch-site G is accepted but with diminished yield.

We applied 6BX22 to synthesize three specific representative biological lariat RNAs that are derived from yeast or mammalian spliceosomal substrates but share no sequence elements outside of the small consensus region. The three RNAs are the 69-nt yeast YBL059W intron with a 51-nt lariat loop,^[15] the 130-nt human β -globin IVS1 intron with a 94-nt loop,^[16] and the 309-nt yeast actin (ACT1) intron with a 266-nt loop.^[17] In each case, a linear 5'-triphosphate substrate was prepared by in vitro transcription using T7 RNA polymerase. Using the linear substrate, the small YBL059W lariat was readily synthesized by 6BX22 in one step and in high yield (Figure 3a). The larger β -globin and ACT1 lariats were also readily prepared (Figures 3b and 3c). The lariats were formed with k_{obs} values comparable to those for the analogous branches, or in the case of β -globin about six-fold slower (but still with useful k_{obs}). Compelling evidence for each lariat structure was provided by several biochemical assays, in which the lariat RNA was cleaved using the 10–23 deoxyribozyme^[18] and yeast debranching enzyme^[19] to generate the predicted pattern of gel bands (see Supporting Information). For the β -globin lariat, disruptor DNA oligonucleotides were required to allow the deoxyribozyme to bind productively with its RNA substrates (see Supporting Information). For the largest ACT1 lariat, a disruptor helped to prevent RNA degradation, but it was not required for high lariat yield (data not shown).

The yeast ACT1 intron is a particularly common model system for studying spliceosomal RNA processing.^[17,20] Artificial synthesis of such lariats without using the natural splicing machinery will enable many biochemical experiments, because the sequence requirements of the spliceosome need not be obeyed. For example, the tolerance of 6BX22 for changes to the branch-site nucleotide during branch formation (Figure 2c) is maintained for lariat synthesis (Figure 3c). Therefore, for the first time, biochemists have access to “real” spliceosomal lariats with mutations at their key branch-site nucleotides. To enable such experiments, preparative-scale (nanomole) synthesis of the ACT1 intron lariat was achieved in high yield (Figure 4).

In summary, we have demonstrated that the 6BX22 deoxyribozyme catalyzes efficient and general one-step lariat synthesis as applied to biological RNAs that are derived from commonly studied yeast and mammalian spliceosomal substrates. The resulting lariats are essentially impossible to synthesize by traditional organic and solid-phase synthesis methods. The only available approach until now has required the use of natural splicing enzymes, which have severe sequence requirements and thereby impose considerable limitations on the RNA sequences that may be used as substrates. Lariat RNA formation for the YBL059W, β -globin, and ACT1 intron substrates corresponds to creation of rings with 307, 565, and 1597 atoms, respectively. These DNA-catalyzed macrocyclization reactions succeed without the use of any protecting groups despite hundreds of competitive 2'-hydroxyl nucleophiles, thereby demonstrating an extremely high level of site-selectivity. The reactions also produce very small amounts of side products such as RNA substrate oligomers that are created in large quantities with other deoxyribozymes that synthesize lariat RNA in low yield.^[6] The broadly useful lariat synthesis ability of 6BX22 is unique as compared with all of our other deoxyribozymes identified to date, including those deoxyribozymes such as 7S11 that are quite general for simpler branched RNA formation.^[8] The structural basis by which 6BX22—but none of our other deoxyribozymes—readily tolerates a closed RNA loop in its catalytically active conformation requires further study, as does the mechanism by which 6BX22 achieves its $>10^5$ -fold rate enhancement over merely templating. In ongoing efforts, we are investigating these fundamental features of catalytic DNA, and we are using synthetic lariats created by 6BX22 to examine key biochemical aspects of RNA splicing.

Experimental Section

Systematic variation of RNA substrate sequences (Figure 2): The original left-hand (L) RNA substrate sequence (which corresponds to that used in the selection procedure^[12]) was 5'-GGAAGUCUCAUGUACUAACA-3'. The original right-hand (R) RNA substrate sequence was 5'-GUAUGUUCUAGCGCGGA-3'. Together these sequences comprise the "core" of the ACT1 branch. For the experiment shown in Figure 2b, nearly all RNA substrate nucleotides in both L and R were changed by transversions ($A \leftrightarrow C$ and $G \leftrightarrow U$). In L, changes were made to all nucleotides from the 5'-end through and including UACU. In R, changes were made to all nucleotides after 5'-GU through the 3'-end. In all cases, corresponding transversions were made to the DNA to maintain Watson-Crick complementarity. For the experiment shown in Figure 2c, the L substrate was varied only at the branch-site nucleotide position (UACUAAC). For experiments with variations at the L substrate UACUA nucleotide and at the R substrate GUU nucleotide, see the Supporting Information. Variation of the 5'-triphosphorylated guanosine (5'-pppG) of the R substrate was not tested. The assays used 5'-³²P-radiolabeled L substrate and L:deoxyribozyme:R = 1:3:6, with incubation conditions of 50 mM HEPES, pH 7.5, 150 mM NaCl, 2 mM KCl, and 20 mM MnCl₂ at 37 °C.

Synthesis of the three lariat RNAs (Figure 3): Each linear RNA substrate was prepared by transcription using α -³²P-CTP, such that the transcript was internally ³²P-radiolabeled. The assays used the above incubation conditions and a ratio substrate:deoxyribozyme = 1:2. In all cases, side products (which are presumably substrate oligomers^[6]) were observed in very small amounts: <3% yield for YBL059W and for β -globin; <0.1% yield for ACT1 (data not shown).

Preparative ACT1 lariat synthesis (Figure 4): The preparative lariat formation reaction was performed as follows. A sample was prepared that contained 1.0 nmol of linear substrate and 1.5 nmol of deoxyribozyme plus 2.0 nmol of the disruptor DNA oligonucleotide (see Supporting Information) in 150 μ L of 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA. The sample was annealed by heating at 95 °C for 3 min and then cooling on ice for 5 min. The volume was increased to 200 μ L containing 50 mM HEPES, pH 7.5, 150 mM NaCl, 2 mM KCl, and 20 mM MnCl₂; the Mn²⁺ was added from a 1 M aqueous stock solution. The 200-

μL solution was incubated at 37 °C for 1.5 h and then mixed with 300 μL of low-dye stop solution (80% formamide, 1 $\times$ TBE [89 mM each Tris and boric acid, pH 8.3], and 0.0025% each xylene cyanol and bromophenol blue). The sample was electrophoresed on 6% PAGE and visualized by UV shadowing; the lariat product was extracted and ethanol-precipitated as described.^[7] The isolated yield of lariat RNA product (after gel extraction and ethanol precipitation) was 0.39 nmol starting from 1.0 nmol of linear substrate. This 39% yield (compared with the 70% yield observed on analytical scale without PAGE purification; Figure 3c) reflects losses that are commonly observed during extraction and precipitation of large RNAs from polyacrylamide gels.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References

1. Peebles CL, Perlman PS, Mecklenburg KL, Petrillo ML, Tabor JH, Jarrell KA, Cheng HL. *Cell* 1986;44:213. [PubMed: 3510741]
2. C. B. Burge, T. Tuschl, P. A. Sharp, in *The RNA World*, 2nd ed. (Eds.: R. F. Gesteland, T. R. Cech, J. F. Atkins), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1999, pp. 525.
3. Sund C, Agback P, Chattopadhyaya J. Sund C, Agback P, Chattopadhyaya J. Reese CB, Song Q. Carriero S, Damha MJ. *Tetrahedron Tetrahedron Nucleic Acids Res J Org Chem* 1991;1993;1999;2003;47492768:9659. 649, 2672, 8328.
4. Damha MJ, Ganeshan K, Hudson RH, Zabarylo SV, Sproat BS, Beijer B, Grøtli M, Ryder U, Morand KL, Lamond AI. von Büren M, Petersen GV, Rasmussen K, Brandenburg G, Wengel J. Grøtli M, Eritja R, Sproat B. *Nucleic Acids Res J Chem Soc Perkin Trans 1 Tetrahedron Tetrahedron* 1992;1994;1995;1997;205153:6565. 419, 8491, 11317. [PubMed: 1480476]
5. Silverman SK, Achenbach JC, Chiuman W, Cruz RP, Li Y, Emilsson GM, Breaker RR, Lu Y. *Org Biomol Chem Curr Pharm Biotechnol Cell Mol Life Sci Chem Eur J* 2004;2004;2002;2002;25598:2701. 321, 596, 4589. [PubMed: 15455136]
6. Wang Y, Silverman SK. *J Am Chem Soc* 2003;125:6880. [PubMed: 12783536]
7. Wang Y, Silverman SK. *Biochemistry* 2003;42:15252. [PubMed: 14690435]
8. Coppins RL, Silverman SK. Coppins RL, Silverman SK. *Nature Struct Mol Biol J Am Chem Soc* 2004;2005;11127:270. 2900. [PubMed: 14758353]
9. Pratico ED, Wang Y, Silverman SK. *Nucleic Acids Res* 2005;33in press
10. For example, see the Supporting Information for secondary structures of two of the RNAs studied in this report.
11. Joyce GF, Wilson DS, Szostak JW. *Annu Rev Biochem Annu Rev Biochem* 2004;1999;7368:791. 611. [PubMed: 15189159]
12. Wang Y, Silverman SK. *Biochemistry* 2005;44:3017. [PubMed: 15723545]
13. If one or more (e.g., 39) random DNA nucleotides are included between the DNA binding arms in place of the enzyme region, then $k_{\text{templated}}$ decreases considerably (data not shown). Therefore, the 6BX22 rate enhancement calculated using $k_{\text{templated}}$ for the DNA template that lacks any enzyme region is a conservative estimate (i.e., a lower limit). Additionally, because the templated background product is almost certainly linear and not branched RNA^[14] (insufficient amounts of this product are available for analysis), the $k_{\text{templated}}$ for forming the branched product that 6BX22 actually synthesizes must be lower than the experimentally measured $k_{\text{templated}}$. This further contributes to the calculated rate enhancement being a lower limit.
14. Rohatgi R, Bartel DP, Szostak JW. *J Am Chem Soc* 1996;118:3340. [PubMed: 11539268]
15. Davis CA, Grate L, Spingola M, Ares M Jr. Grate L, Ares M Jr. *Nucleic Acids Res Methods Enzymol* 2000;2002;28350:1700. 380. [PubMed: 10734188]
16. Spritz RA, Jagadeeswaran P, Choudary PV, Biro PA, Elder JT, deRiel JK, Manley JL, Gefter ML, Forget BG, Weissman SM. Reed R, Maniatis T. Hall KB, Green MR, Redfield AG. *Proc Natl Acad Sci USA Cell Proc Natl Acad Sci USA* 1981;1985;1988;784185:2455. 95, 704. [PubMed: 6264477]

17. Ng R, Abelson J. Proc Natl Acad Sci USA 1980;77:3912. [PubMed: 7001447]
18. Santoro SW, Joyce GF. Proc Natl Acad Sci USA 1997;94:4262. [PubMed: 9113977]
19. Ooi SL, Dann C 3rd, Nam K, Leahy DJ, Damha MJ, Boeke JD. Nam K, Hudson RH, Chapman KB, Ganeshan K, Damha MJ, Boeke JD. Methods Enzymol J Biol Chem 2001;1994:342269:233. 20613. [PubMed: 11586896]
20. Staley JP, Guthrie C. Mol Cell 1999;3:55. [PubMed: 10024879]

Figure 1.

Lariat RNA and its synthesis by a deoxyribozyme. a) Connectivity of lariat RNA and 2',5'-branched RNA. The latter has the same branch-site nucleotide as a lariat but lacks the closed loop. The four illustrated nucleotides constitute the minimal part of a 2',5'-branched RNA. b) Deoxyribozyme-catalyzed synthesis of lariat RNA.

Figure 2.

Branched RNA formation by the 6BX22 deoxyribozyme. a) Using yeast spliceosomal substrate sequences; the conserved nucleotides are shown explicitly.^[2] As demonstrated with the comprehensive experiments shown here and in the Supporting Information, 6BX22 tolerates nucleotide changes at most of the conserved positions; the sites of tolerance are indicated with uppercase letters. The second nucleotide (U) of the R substrate prefers U, C, or A over G. The sequence of the enzyme region of 6BX22 (i.e., the 39 nucleotides not base-paired with the RNA substrates) is given below the structure. The Watson-Crick binding arms of the DNA are shown in light grey. See Experimental Section for full sequences of the left-hand (L) and right-hand (R) substrates. b) Demonstrating generality of 6BX22 for its RNA substrate sequences. Conditions: 50 mM HEPES, pH 7.5, 150 mM NaCl, 2 mM KCl, 20 mM MnCl₂, 37 °C.

Triangles, original RNA sequences (which correspond to the core nucleotides of the ACT1 RNA). Circles, variant RNA sequences (see Experimental Section). For this experiment, $k_{\text{obs}} = 0.077 \pm 0.007 \text{ min}^{-1}$ (original sequences) and $0.066 \pm 0.004 \text{ min}^{-1}$ (variant sequences); errors are standard deviations from exponential curve fits. c) Demonstrating generality of 6BX22 for branch-site nucleotides ($t = 0, 0.5$, and 1.5 h with $5'$ - ^{32}P -radiolabeled L substrate; 20% PAGE). Yields at 1.5 h timepoint: branch-site A, 71%; G, 5%, C, 33%, U, 64% ($k_{\text{rel}} = 1, 0.085, 0.097$, and 0.027 ; data not shown). In all cases, partial alkaline hydrolysis of the branched product^[6] verified that the site of branching remained unchanged (data not shown).

Figure 3.

Formation of biologically related lariat RNAs using the 6BX22 deoxyribozyme. a) Synthesis of the 69-nt YBL059W lariat, which has a 51-nt loop (12% PAGE; $t = 0, 0.5$, and 1.5 h). Yield at 1.5 h timepoint, 52%; $k_{\text{obs}} = 1.1 \text{ h}^{-1}$ (data not shown). b) Synthesis of the 130-nt human β -globin IVS1 lariat, which has a 94-nt loop (8% PAGE; $t = 0, 2$, and 6 h). Yield at 6 h timepoint, 33%; $k_{\text{obs}} = 0.17 \text{ h}^{-1}$. At a 24 -h timepoint, the yield was $\sim 50\%$, but some nonspecific RNA degradation was evident (data not shown). c) Synthesis of the 309-nt ACT1 lariat, which has a 266-nt loop; this was tested with mutants in which the branch-site nucleotide was changed as indicated (6% PAGE; $t = 0, 0.5$, and 1.5 h). Yields at 1.5 h timepoint: branch-site A, 72%; G, 9%, C, 48%, U, 70%. k_{obs} for branch-site A = 2.8 h^{-1} (data not shown). For the β -globin lariat, disruptor DNA oligonucleotides were required to sequester RNA secondary structure and enable binding of the DNA enzyme to the RNA substrates (see Supporting Information). Without disruptors, the β -globin lariat yield was 0.3% at 6 h. A disruptor oligonucleotide was helpful but not absolutely required for ACT1 lariat synthesis, primarily by modestly enhancing the ligation rate (by less than two-fold) and by suppressing nonspecific RNA degradation.

Preparative ACT1 lariat synthesis

Figure 4. Preparative synthesis of the ACT1 lariat RNA. The image was recorded by UV shadowing of the 6% polyacrylamide gel.